AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pletz, M. W. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pletz, M. W. R.
Antimicrobial Agents and Chemotherapy, April 2006, p. 1561-1563, Vol. 50, No. 4
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.4.1561-1563.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Prevalence of First-Step Mutants among Levofloxacin-Susceptible Invasive Isolates of Streptococcus pneumoniae in the United States

Mathias W. R. Pletz,1,2,3* Ardaman P. Shergill,1 Lesley McGee,1,3 Bernard Beall,3 Cynthia G. Whitney,3 Keith P. Klugman,1,3 for the Active Bacterial Core Surveillance Team,3

Hubert Department of Global Health, Rollins School of Public Health, and Division of Infectious Diseases, School of Medicine, Emory University, Atlanta, Georgia,1 Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany,2 Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia3

Received 19 July 2005/ Returned for modification 31 October 2005/ Accepted 25 January 2006

By use of a PCR-restriction fragment length polymorphism assay, we screened 496 levofloxacin-susceptible invasive pneumococcal strains (MIC ≤ 2 mg/liter) for quinolone resistance-determining region mutations known to confer fluoroquinolone resistance. Among those with a levofloxacin MIC of 2 mg/liter, 16.2% of isolates recovered from nursing home residents and 6.4% from non-nursing home residents had first-step mutations.

* Corresponding author. Mailing address: Department of Respiratory Medicine, Hannover Medical School, Carl-Neuberg-Str. 1, Hannover 30625, Germany. Phone: 49 (511) 532-9612. Fax: 49 (511) 532-8419. E-mail: Pletz.Mathias{at}mh-hannover.de.

Antimicrobial Agents and Chemotherapy, April 2006, p. 1561-1563, Vol. 50, No. 4
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.4.1561-1563.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2006 by the American Society for Microbiology. All rights reserved.